mortality/aging
• following crosses between homozygous males and heterozygous females, homozygous mutant mice are obtained at a slightly reduced Mendelian frequency at ~P21 (weaning)
|
cellular
• cycloheximide-treated MEFs show a significantly lower p53 half-life than similarly treated wild-type MEFs, indicating increased p53 degradation
|
• mice show significant resistance to etoposide-induced apoptosis in the thymus, spleen and testis, as shown by cleaved caspase-3 immunofluorescence and TUNEL staining
• in vitro, mouse embryo fibroblasts (MEFs) show significantly reduced apoptosis levels in response to etoposide or camptothecin treatment relative to wild-type MEFs
• however, thymocytes show normal levels of apoptosis induced by dexamethasone, a p53-independent apoptogenic stimulus
|
• mice do not undergo p53-driven mitochondrial apoptosis
|
• etoposide-treated mice fail to show an accumulation of p53 mitochondrial protein levels in thymus, spleen and testis, unlike similarly treated wild-type mice
• in vitro, etoposide-treated thymocytes and splenocytes show a lower mitochondrial accumulation of p53 and higher cell viability relative to similarly treated wild-type cells
• etoposide-treated MEFs stained with vital dye JC-1 show a reduction in p53-dependent mitochondrial membrane potential loss relative to similarly treated wild-type MEFs
• however, mitochondria isolated from MEFs show normal cytochrome c release after addition of recombinant p53, indicating normal mitochondrial outer membrane permeability
|
reproductive system
• homozygous mice show a reduced ability to produce offspring
|